XML 76 R53.htm IDEA: XBRL DOCUMENT
v3.23.2

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jul. 02, 2023 | Jul. 03, 2022 | Jul. 02, 2023 | Jul. 03, 2022
Sales by segment of business |  |  |  |
Sales to customers | $ 25,530 | $ 24,020 | $ 50,276 | $ 47,446
Percent Change (as a percent) | 6.30% |  | 6.00% |
U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 13,444 | 12,197 | $ 25,961 | 23,611
Percent Change (as a percent) | 10.20% |  | 10.00% |
International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 12,086 | 11,823 | $ 24,315 | 23,835
Percent Change (as a percent) | 2.20% |  | 2.00% |
CONSUMER HEALTH |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 4,011 | 3,805 | $ 7,863 | 7,391
Percent Change (as a percent) | 5.40% |  | 6.40% |
CONSUMER HEALTH | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,787 | 1,687 | $ 3,522 | 3,244
Percent Change (as a percent) | 6.00% |  | 8.60% |
CONSUMER HEALTH | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,224 | 2,118 | $ 4,341 | 4,147
Percent Change (as a percent) | 5.00% |  | 4.70% |
CONSUMER HEALTH | OTC [Member] |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,659 | 1,482 | $ 3,301 | 2,943
Percent Change (as a percent) | 12.00% |  | 12.20% |
CONSUMER HEALTH | OTC [Member] | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 712 | 663 | $ 1,457 | 1,333
Percent Change (as a percent) | 7.50% |  | 9.30% |
CONSUMER HEALTH | OTC [Member] | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 947 | 818 | $ 1,844 | 1,609
Percent Change (as a percent) | 15.70% |  | 14.60% |
CONSUMER HEALTH | Skin Health/Beauty |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,148 | 1,126 | $ 2,258 | 2,138
Percent Change (as a percent) | 2.00% |  | 5.60% |
CONSUMER HEALTH | Skin Health/Beauty | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 650 | 629 | $ 1,267 | 1,173
Percent Change (as a percent) | 3.40% |  | 8.00% |
CONSUMER HEALTH | Skin Health/Beauty | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 498 | 497 | $ 991 | 965
Percent Change (as a percent) | 0.30% |  | 2.70% |
CONSUMER HEALTH | Oral Care |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 398 | 394 | $ 759 | 760
Percent Change (as a percent) | 0.90% |  | (0.20%) |
CONSUMER HEALTH | Oral Care | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 173 | 170 | $ 332 | 313
Percent Change (as a percent) | 1.70% |  | 6.20% |
CONSUMER HEALTH | Oral Care | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 225 | 224 | $ 427 | 447
Percent Change (as a percent) | 0.30% |  | (4.70%) |
CONSUMER HEALTH | Baby Care |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 360 | 375 | $ 719 | 730
Percent Change (as a percent) | (4.00%) |  | (1.60%) |
CONSUMER HEALTH | Baby Care | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 99 | 88 | $ 195 | 173
Percent Change (as a percent) | 12.50% |  | 12.70% |
CONSUMER HEALTH | Baby Care | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 261 | 287 | $ 524 | 557
Percent Change (as a percent) | (9.10%) |  | (6.00%) |
CONSUMER HEALTH | Women’s Health |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 238 | 230 | $ 455 | 458
Percent Change (as a percent) | 3.40% |  | (0.60%) |
CONSUMER HEALTH | Women’s Health | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 4 | 3 | $ 7 | 7
Percent Change (as a percent) | (2.10%) |  | (0.10%) |
CONSUMER HEALTH | Women’s Health | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 235 | 228 | $ 449 | 452
Percent Change (as a percent) | 3.50% |  | (0.70%) |
CONSUMER HEALTH | Wound Care/Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 207 | 197 | $ 371 | 361
Percent Change (as a percent) | 4.90% |  | 2.60% |
CONSUMER HEALTH | Wound Care/Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 149 | 133 | $ 264 | 245
Percent Change (as a percent) | 12.30% |  | 7.90% |
CONSUMER HEALTH | Wound Care/Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 58 | 65 | $ 107 | 117
Percent Change (as a percent) | (10.30%) |  | (8.40%) |
PHARMACEUTICAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 13,731 | 13,317 | $ 27,144 | 26,186
Percent Change (as a percent) | 3.10% |  | 3.70% |
PHARMACEUTICAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 7,818 | 7,159 | $ 14,841 | 13,791
Percent Change (as a percent) | 9.20% |  | 7.60% |
PHARMACEUTICAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 5,913 | 6,158 | $ 12,303 | 12,395
Percent Change (as a percent) | (4.00%) |  | (0.70%) |
PHARMACEUTICAL | Immunology |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 4,496 | 4,411 | $ 8,608 | 8,530
Percent Change (as a percent) | 1.90% |  | 0.90% |
PHARMACEUTICAL | Immunology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,865 | 2,853 | $ 5,313 | 5,354
Percent Change (as a percent) | 0.40% |  | (0.80%) |
PHARMACEUTICAL | Immunology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,631 | 1,559 | $ 3,295 | 3,176
Percent Change (as a percent) | 4.70% |  | 3.80% |
PHARMACEUTICAL | Immunology | REMICADE |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 462 | 647 | $ 949 | 1,310
Percent Change (as a percent) | (28.60%) |  | (27.50%) |
PHARMACEUTICAL | Immunology | REMICADE | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 277 | 391 | $ 553 | 749
Percent Change (as a percent) | (29.30%) |  | (26.20%) |
PHARMACEUTICAL | Immunology | REMICADE | U.S. Exports |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 33 | 44 | $ 74 | 124
Percent Change (as a percent) | (24.90%) |  | (40.30%) |
PHARMACEUTICAL | Immunology | REMICADE | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 152 | 212 | $ 322 | 437
Percent Change (as a percent) | (28.20%) |  | (26.20%) |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 529 | 566 | $ 1,066 | 1,137
Percent Change (as a percent) | (6.60%) |  | (6.20%) |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 285 | 301 | $ 556 | 588
Percent Change (as a percent) | (5.10%) |  | (5.40%) |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 244 | 266 | $ 510 | 549
Percent Change (as a percent) | (8.20%) |  | (7.10%) |
PHARMACEUTICAL | Immunology | STELARA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,797 | 2,599 | $ 5,241 | 4,887
Percent Change (as a percent) | 7.60% |  | 7.20% |
PHARMACEUTICAL | Immunology | STELARA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,817 | 1,731 | $ 3,268 | 3,110
Percent Change (as a percent) | 4.90% |  | 5.10% |
PHARMACEUTICAL | Immunology | STELARA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 981 | 868 | $ 1,974 | 1,777
Percent Change (as a percent) | 13.00% |  | 11.10% |
PHARMACEUTICAL | Immunology | TREMFYA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 706 | 597 | $ 1,346 | 1,187
Percent Change (as a percent) | 18.30% |  | 13.40% |
PHARMACEUTICAL | Immunology | TREMFYA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 450 | 382 | $ 856 | 773
Percent Change (as a percent) | 17.80% |  | 10.70% |
PHARMACEUTICAL | Immunology | TREMFYA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 255 | 214 | $ 489 | 413
Percent Change (as a percent) | 19.40% |  | 18.40% |
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 4 | 3 | $ 7 | 9
Percent Change (as a percent) | 17.80% |  | (30.20%) |
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 4 | 3 | $ 7 | 9
Percent Change (as a percent) | 17.80% |  | (30.20%) |
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
PHARMACEUTICAL | Infectious Diseases |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,121 | 1,316 | $ 2,707 | 2,613
Percent Change (as a percent) | (14.80%) |  | 3.60% |
PHARMACEUTICAL | Infectious Diseases | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 395 | 415 | $ 787 | 876
Percent Change (as a percent) | (4.90%) |  | (10.20%) |
PHARMACEUTICAL | Infectious Diseases | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 727 | 901 | $ 1,920 | 1,737
Percent Change (as a percent) | (19.40%) |  | 10.50% |
PHARMACEUTICAL | Infectious Diseases | COVID-19 |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 285 | 544 | $ 1,032 | 1,001
Percent Change (as a percent) | (47.70%) |  | 3.00% |
PHARMACEUTICAL | Infectious Diseases | COVID-19 | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 45 | $ 0 | 120
PHARMACEUTICAL | Infectious Diseases | COVID-19 | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 285 | 499 | $ 1,032 | 881
Percent Change (as a percent) | (43.00%) |  | 17.10% |
PHARMACEUTICAL | Infectious Diseases | EDURANT / rilpivirine |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 266 | 225 | $ 546 | 473
Percent Change (as a percent) | 18.60% |  | 15.60% |
PHARMACEUTICAL | Infectious Diseases | EDURANT / rilpivirine | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 8 | 9 | $ 17 | 18
Percent Change (as a percent) | (9.00%) |  | (5.30%) |
PHARMACEUTICAL | Infectious Diseases | EDURANT / rilpivirine | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 258 | 215 | $ 529 | 454
Percent Change (as a percent) | 19.90% |  | 16.40% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 491 | 464 | $ 968 | 965
Percent Change (as a percent) | 5.80% |  | 0.30% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 382 | 355 | $ 760 | 724
Percent Change (as a percent) | 7.60% |  | 5.00% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 109 | 110 | $ 208 | 242
Percent Change (as a percent) | (0.20%) |  | (13.90%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES( |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 79 | 83 | $ 161 | 174
Percent Change (as a percent) | (5.20%) |  | (7.60%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES( | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 5 | 6 | $ 10 | 14
Percent Change (as a percent) | (27.20%) |  | (30.60%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES( | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 74 | 77 | $ 151 | 160
Percent Change (as a percent) | (3.50%) |  | (5.60%) |
PHARMACEUTICAL | Neuroscience |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,793 | 1,734 | $ 3,597 | 3,475
Percent Change (as a percent) | 3.50% |  | 3.50% |
PHARMACEUTICAL | Neuroscience | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,029 | 896 | $ 2,007 | 1,739
Percent Change (as a percent) | 14.90% |  | 15.40% |
PHARMACEUTICAL | Neuroscience | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 764 | 837 | $ 1,590 | 1,735
Percent Change (as a percent) | (8.80%) |  | (8.40%) |
PHARMACEUTICAL | Neuroscience | CONCERTA / methylphenidate |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 208 | 161 | $ 414 | 318
Percent Change (as a percent) | 28.60% |  | 30.00% |
PHARMACEUTICAL | Neuroscience | CONCERTA / methylphenidate | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 64 | 38 | $ 134 | 73
Percent Change (as a percent) | 68.20% |  | 84.00% |
PHARMACEUTICAL | Neuroscience | CONCERTA / methylphenidate | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 143 | 123 | $ 279 | 245
Percent Change (as a percent) | 16.30% |  | 13.90% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,031 | 1,054 | $ 2,075 | 2,102
Percent Change (as a percent) | (2.10%) |  | (1.30%) |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 721 | 691 | $ 1,434 | 1,352
Percent Change (as a percent) | 4.30% |  | 6.00% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 310 | 362 | $ 641 | 749
Percent Change (as a percent) | (14.40%) |  | (14.50%) |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 386 | 433 | $ 809 | 900
Percent Change (as a percent) | (10.90%) |  | (10.10%) |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 100 | 93 | $ 184 | 179
Percent Change (as a percent) | 9.30% |  | 3.10% |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 286 | 341 | $ 625 | 721
Percent Change (as a percent) | (16.40%) |  | (13.40%) |
PHARMACEUTICAL | Neuroscience | SPRAVATO |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 169 | 85 | $ 300 | 155
Percent Change (as a percent) | 98.20% |  | 93.10% |
PHARMACEUTICAL | Neuroscience | SPRAVATO | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 144 | 74 | $ 255 | 135
Percent Change (as a percent) | 93.20% |  | 88.30% |
PHARMACEUTICAL | Neuroscience | SPRAVATO | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 25 | 11 | $ 45 | 20
PHARMACEUTICAL | Oncology |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 4,398 | 4,042 | $ 8,510 | 7,992
Percent Change (as a percent) | 8.80% |  | 6.50% |
PHARMACEUTICAL | Oncology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,069 | 1,679 | $ 3,958 | 3,261
Percent Change (as a percent) | 23.20% |  | 21.40% |
PHARMACEUTICAL | Oncology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,329 | 2,362 | $ 4,552 | 4,731
Percent Change (as a percent) | (1.40%) |  | (3.80%) |
PHARMACEUTICAL | Oncology | DARZALEX |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,431 | 1,986 | $ 4,695 | 3,842
Percent Change (as a percent) | 22.40% |  | 22.20% |
PHARMACEUTICAL | Oncology | DARZALEX | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,322 | 1,021 | $ 2,513 | 1,974
Percent Change (as a percent) | 29.50% |  | 27.30% |
PHARMACEUTICAL | Oncology | DARZALEX | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,110 | 965 | $ 2,182 | 1,868
Percent Change (as a percent) | 15.00% |  | 16.80% |
PHARMACEUTICAL | Oncology | ERLEADA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 567 | 450 | $ 1,109 | 850
Percent Change (as a percent) | 25.90% |  | 30.40% |
PHARMACEUTICAL | Oncology | ERLEADA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 241 | 233 | $ 490 | 439
Percent Change (as a percent) | 3.60% |  | 11.80% |
PHARMACEUTICAL | Oncology | ERLEADA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 326 | 218 | $ 619 | 412
Percent Change (as a percent) | 49.70% |  | 50.30% |
PHARMACEUTICAL | Oncology | IMBRUVICA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 841 | 970 | $ 1,668 | 2,008
Percent Change (as a percent) | (13.20%) |  | (16.90%) |
PHARMACEUTICAL | Oncology | IMBRUVICA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 262 | 349 | $ 532 | 719
Percent Change (as a percent) | (24.90%) |  | (26.00%) |
PHARMACEUTICAL | Oncology | IMBRUVICA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 579 | 620 | $ 1,136 | 1,288
Percent Change (as a percent) | (6.70%) |  | (11.80%) |
PHARMACEUTICAL | Oncology | ZYTIGA / abiraterone acetate |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 227 | 505 | $ 472 | 1,044
Percent Change (as a percent) | (55.10%) |  | (54.80%) |
PHARMACEUTICAL | Oncology | ZYTIGA / abiraterone acetate | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 9 | 19 | $ 25 | 38
Percent Change (as a percent) | (55.20%) |  | (34.70%) |
PHARMACEUTICAL | Oncology | ZYTIGA / abiraterone acetate | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 218 | 486 | $ 447 | 1,006
Percent Change (as a percent) | (55.10%) |  | (55.60%) |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 214 | 106 | $ 376 | 224
Percent Change (as a percent) |  |  | 68.00% |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 122 | 33 | $ 214 | 67
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 92 | 72 | $ 162 | 156
Percent Change (as a percent) | 27.80% |  | 3.60% |
PHARMACEUTICAL | Oncology | CARVYKTI |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 117 | 24 | $ 189 | 24
PHARMACEUTICAL | Oncology | CARVYKTI | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 114 | 24 | 184 | 24
PHARMACEUTICAL | Oncology | CARVYKTI | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 3 | 0 | 5 | 0
PHARMACEUTICAL | Pulmonary Hypertension |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 972 | 843 | $ 1,844 | 1,695
Percent Change (as a percent) | 15.30% |  | 8.80% |
PHARMACEUTICAL | Pulmonary Hypertension | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 684 | 560 | $ 1,284 | 1,132
Percent Change (as a percent) | 22.00% |  | 13.40% |
PHARMACEUTICAL | Pulmonary Hypertension | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 289 | 284 | $ 561 | 563
Percent Change (as a percent) | 2.00% |  | (0.40%) |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 507 | 438 | $ 947 | 881
Percent Change (as a percent) | 15.70% |  | 7.50% |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 328 | 265 | $ 601 | 538
Percent Change (as a percent) | 23.70% |  | 11.60% |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 179 | 173 | $ 346 | 343
Percent Change (as a percent) | 3.40% |  | 0.90% |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 399 | 328 | $ 761 | 653
Percent Change (as a percent) | 21.80% |  | 16.60% |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 338 | 272 | $ 642 | 541
Percent Change (as a percent) | 24.20% |  | 18.70% |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 61 | 56 | $ 119 | 112
Percent Change (as a percent) | 10.00% |  | 6.60% |
PHARMACEUTICAL | Pulmonary Hypertension | Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 66 | 78 | $ 136 | 161
Percent Change (as a percent) | (14.70%) |  | (15.50%) |
PHARMACEUTICAL | Pulmonary Hypertension | Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 18 | 23 | $ 41 | 53
Percent Change (as a percent) | (23.80%) |  | (23.00%) |
PHARMACEUTICAL | Pulmonary Hypertension | Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 48 | 55 | $ 95 | 108
Percent Change (as a percent) | (10.90%) |  | (11.70%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 950 | 972 | $ 1,877 | 1,882
Percent Change (as a percent) | (2.20%) |  | (0.30%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 776 | 757 | $ 1,491 | 1,429
Percent Change (as a percent) | 2.60% |  | 4.30% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 174 | 215 | $ 386 | 453
Percent Change (as a percent) | (19.00%) |  | (14.70%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 637 | 609 | $ 1,215 | 1,117
Percent Change (as a percent) | 4.70% |  | 8.80% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 637 | 609 | $ 1,215 | 1,117
Percent Change (as a percent) | 4.70% |  | 8.80% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 313 | 363 | $ 662 | 765
Percent Change (as a percent) | (13.80%) |  | (13.50%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 138 | 148 | $ 275 | 312
Percent Change (as a percent) | (6.30%) |  | (11.80%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 174 | 215 | $ 386 | 453
Percent Change (as a percent) | (19.00%) |  | (14.70%) |
MEDTECH |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 7,788 | 6,898 | $ 15,269 | 13,869
Percent Change (as a percent) | 12.90% |  | 10.10% |
MEDTECH | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,839 | 3,351 | $ 7,598 | 6,576
Percent Change (as a percent) | 14.60% |  | 15.50% |
MEDTECH | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,949 | 3,547 | $ 7,671 | 7,293
Percent Change (as a percent) | 11.30% |  | 5.20% |
MEDTECH | Interventional Solutions |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,620 | 1,049 | $ 3,123 | 2,141
Percent Change (as a percent) | 54.40% |  | 45.80% |
MEDTECH | Interventional Solutions | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 908 | 525 | $ 1,771 | 1,019
Percent Change (as a percent) | 73.10% |  | 73.80% |
MEDTECH | Interventional Solutions | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 712 | 525 | $ 1,352 | 1,123
Percent Change (as a percent) | 35.70% |  | 20.50% |
MEDTECH | ELECTROPHYSIOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,196 | 968 | $ 2,288 | 1,970
Percent Change (as a percent) | 23.50% |  | 16.20% |
MEDTECH | ELECTROPHYSIOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 609 | 499 | $ 1,180 | 969
Percent Change (as a percent) | 22.00% |  | 21.70% |
MEDTECH | ELECTROPHYSIOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 587 | 469 | $ 1,109 | 1,001
Percent Change (as a percent) | 25.10% |  | 10.80% |
MEDTECH | ABIOMED(3) |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 331 | 0 | $ 655 | 0
MEDTECH | ABIOMED(3) | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 272 | 0 | 536 | 0
MEDTECH | ABIOMED(3) | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 59 | 0 | 119 | 0
MEDTECH | OTHER INTERVENTIONAL SOLUTIONS |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 93 | 81 | $ 180 | 171
Percent Change (as a percent) | 15.10% |  | 5.10% |
MEDTECH | OTHER INTERVENTIONAL SOLUTIONS | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 27 | 26 | $ 55 | 51
Percent Change (as a percent) | 4.50% |  | 10.80% |
MEDTECH | OTHER INTERVENTIONAL SOLUTIONS | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 67 | 56 | $ 125 | 121
Percent Change (as a percent) | 20.00% |  | 2.80% |
MEDTECH | Orthopaedics |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,265 | 2,157 | $ 4,510 | 4,345
Percent Change (as a percent) | 5.00% |  | 3.80% |
MEDTECH | Orthopaedics | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,388 | 1,338 | $ 2,751 | 2,627
Percent Change (as a percent) | 3.70% |  | 4.70% |
MEDTECH | Orthopaedics | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 878 | 820 | $ 1,759 | 1,719
Percent Change (as a percent) | 7.00% |  | 2.30% |
MEDTECH | Orthopaedics | HIPS |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 397 | 388 | $ 787 | 777
Percent Change (as a percent) | 2.20% |  | 1.30% |
MEDTECH | Orthopaedics | HIPS | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 250 | 240 | $ 491 | 465
Percent Change (as a percent) | 4.10% |  | 5.60% |
MEDTECH | Orthopaedics | HIPS | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 147 | 148 | $ 296 | 312
Percent Change (as a percent) | (0.80%) |  | (5.10%) |
MEDTECH | Orthopaedics | KNEES |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 363 | 349 | $ 731 | 688
Percent Change (as a percent) | 3.90% |  | 6.30% |
MEDTECH | Orthopaedics | KNEES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 221 | 216 | $ 447 | 417
Percent Change (as a percent) | 2.40% |  | 7.20% |
MEDTECH | Orthopaedics | KNEES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 142 | 133 | $ 284 | 271
Percent Change (as a percent) | 6.30% |  | 4.80% |
MEDTECH | Orthopaedics | TRAUMA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 739 | 696 | $ 1,496 | 1,444
Percent Change (as a percent) | 6.10% |  | 3.60% |
MEDTECH | Orthopaedics | TRAUMA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 483 | 464 | $ 974 | 939
Percent Change (as a percent) | 4.30% |  | 3.70% |
MEDTECH | Orthopaedics | TRAUMA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 255 | 232 | $ 522 | 505
Percent Change (as a percent) | 9.90% |  | 3.20% |
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 766 | 724 | $ 1,495 | 1,436
Percent Change (as a percent) | 5.80% |  | 4.20% |
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 433 | 418 | $ 839 | 805
Percent Change (as a percent) | 3.50% |  | 4.10% |
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 334 | 306 | $ 657 | 630
Percent Change (as a percent) | 9.00% |  | 4.20% |
MEDTECH | Surgery |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,594 | 2,450 | $ 5,028 | 4,884
Percent Change (as a percent) | 5.90% |  | 3.00% |
MEDTECH | Surgery | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,015 | 992 | $ 1,990 | 1,913
Percent Change (as a percent) | 2.20% |  | 4.00% |
MEDTECH | Surgery | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,580 | 1,458 | $ 3,039 | 2,971
Percent Change (as a percent) | 8.40% |  | 2.30% |
MEDTECH | Surgery | ADVANCED |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,222 | 1,156 | $ 2,340 | 2,302
Percent Change (as a percent) | 5.80% |  | 1.70% |
MEDTECH | Surgery | ADVANCED | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 466 | 454 | $ 910 | 871
Percent Change (as a percent) | 2.70% |  | 4.50% |
MEDTECH | Surgery | ADVANCED | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 757 | 702 | $ 1,430 | 1,431
Percent Change (as a percent) | 7.80% |  | 0.00% |
MEDTECH | Surgery | GENERAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,372 | 1,294 | $ 2,688 | 2,582
Percent Change (as a percent) | 6.00% |  | 4.10% |
MEDTECH | Surgery | GENERAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 548 | 538 | $ 1,079 | 1,042
Percent Change (as a percent) | 1.90% |  | 3.60% |
MEDTECH | Surgery | GENERAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 823 | 756 | $ 1,608 | 1,540
Percent Change (as a percent) | 8.90% |  | 4.50% |
MEDTECH | Vision |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,308 | 1,241 | $ 2,608 | 2,498
Percent Change (as a percent) | 5.40% |  | 4.40% |
MEDTECH | Vision | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 529 | 496 | $ 1,087 | 1,017
Percent Change (as a percent) | 6.60% |  | 6.90% |
MEDTECH | Vision | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 778 | 745 | $ 1,521 | 1,481
Percent Change (as a percent) | 4.60% |  | 2.70% |
MEDTECH | Vision | CONTACT LENSES / OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 939 | 894 | $ 1,892 | 1,804
Percent Change (as a percent) | 5.10% |  | 4.90% |
MEDTECH | Vision | CONTACT LENSES / OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 409 | 374 | $ 853 | 774
Percent Change (as a percent) | 9.10% |  | 10.10% |
MEDTECH | Vision | CONTACT LENSES / OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 530 | 519 | $ 1,039 | 1,030
Percent Change (as a percent) | 2.20% |  | 0.90% |
MEDTECH | Vision | SURGICAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 369 | 347 | $ 716 | 694
Percent Change (as a percent) | 6.20% |  | 3.10% |
MEDTECH | Vision | SURGICAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 120 | 122 | $ 234 | 243
Percent Change (as a percent) | (1.10%) |  | (3.60%) |
MEDTECH | Vision | SURGICAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 249 | $ 225 | $ 482 | $ 451
Percent Change (as a percent) | 10.10% |  | 6.70% |

X
- Definition Percentage change in sales by segment of business. + References No definition available. + Details
Name: | jnj_PercentageChangeInSalesBySegmentOfBusiness
Namespace Prefix: | jnj_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_BeautyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OralCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_BabyCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_WomensHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_StelaraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TremfyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_COVID19Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPRAVATOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_DARZALEXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ERLEADAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_IMBRUVICAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ZYTIGAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CARVYKTIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OPSUMITMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_UPTRAVIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_XareltoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ElectrophysiologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_AbiomedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OtherInterventionalSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_HIPSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_KNEESMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TRAUMAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPINEOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ADVANCEDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_GENERALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_VisionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SURGICALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |